RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") reports that U.S. researchers have found that Thymosin Beta 4 (Tβ4) promotes statistically significant recovery of peripheral neuropathy in type II diabetic mice including recovery of neurovascular dysfunction in the sciatic nerve and recovery of neurological function. Peripheral neuropathy is one of the most common complications of diabetes mellitus and affects 60%-70% of patients with diabetes.    

According to the research team, "These data indicate that Tβ4 likely acts on endothelial cells and Schwann cells to preserve and/or restore vascular function in the sciatic nerve which facilitates improvement of peripheral nerve function under diabetic neuropathy. Thus, Tβ4 has potential for the treatment of diabetic peripheral neuropathy."


RegeneRx Biopharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
BIDMC researchers seek to reduce racial and ethnic disparities in diabetes diagnosis